CStone Announces Inclusion of Cejemly ® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline

CStone Announces Inclusion of Cejemly ® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline#CStone #Announces #Inclusion #Cejemly #sugemalimab #FirstLine #Combination #Therapy #NSCLC #ESMO #Guideline